Target intelligence / Profile preview

Folic acid-dependent pathways

Molecular classification
Other (multi-enzyme pathway), Enzyme (includes key enzymes such as dihydrofolate reductase, methionine synthase, serine hydroxymethyltransferase, methylenetetrahydrofolate reductase, etc.), Transporter (includes folate transporters such as SLC46A1), Receptor (includes folate receptors alpha, beta, gamma)
01

Overview

Folic acid-dependent pathways" comprise a network of biochemical processes critical for transferring one-carbon units required for the synthesis of nucleotides, certain amino acids, and methylation reactions. These pathways rely on multiple enzymes (e.g., dihydrofolate reductase, methionine synthase), receptors (folate receptor alpha, beta, gamma), and transporters to metabolize and utilize folic acid and its derivatives. Disruption or inhibition of these pathways can result in cell cycle arrest, anemia, developmental defects, and increased risk for cancer and cardiovascular disease. While specific proteins within these pathways are considered drug targets, the label "folic acid-dependent pathways" refers to a process rather than a single molecular entity; therefore, it is not a canonical name for a therapeutic drug target.

Other names
folate metabolismfolate cycleone-carbon metabolism
02

Mechanism of action

Enzyme inhibition (antifolates inhibit dihydrofolate reductase, thymidylate synthase, others, blocking nucleotide synthesis); Competitive inhibition of folate transporters or receptors; Interference with one-carbon transfer and methylation.

03

Biological functions

DNA synthesis and repairAmino acid metabolism (serine, glycine, methionine, histidine, cysteine)Epigenetic regulation (methylation reactions)Cell proliferationCell cycle progressionMitochondrial protein translationOther (homocysteine metabolism, methyl group transfer)
04

Disease associations

CancerMegaloblastic anemiaCardiovascular disease (via hyperhomocysteinemia)Neurodegenerative diseases (via methylation defects)Other (developmental disorders, birth defects)
05

Safety considerations

Risk of bone marrow suppression with antifolates (e.g., methotrexate)Megaloblastic anemia from pathway deficiency or inhibitionTeratogenicity from folate deficiency (birth defects)Cardiovascular risk from hyperhomocysteinemia
06

Interacting drugs

Methotrexate (inhibits dihydrofolate reductase)

2 more in the full profile.

07

Biomarkers

Plasma/serum folate levels (used to assess deficiency)Homocysteine levels (elevated in folate/B12 deficiency)

Beyond the preview

Go deeper on Folic acid-dependent pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Folic acid-dependent pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call